Floatz logo

Tetanus-Cmv Fusion Peptide Vaccine

Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

City of Hope Medical CentervaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Bortezomib
National Cancer Institute (NCI)
Phase 2B
FILGRASTIM
National Cancer Institute (NCI)
Phase 2B
Vinorelbine
National Cancer Institute (NCI)
Phase 2B
Ifosfamide
National Cancer Institute (NCI)
Phase 2B
cc-5013
Ohio State University Comprehensive Cancer Center
Phase 2B

View all 10 →

Same molecule, other indications

Tetanus-Cmv Fusion Peptide Vaccine is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
CC
Indicative ·
47 / 100
View asset →
acute myeloid leukemia, del(5q31-q32)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →